<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2004-10-4-173-176</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-937</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Антагонисты кальция: выбор терапии при артериальной гипертонии</article-title><trans-title-group xml:lang="en"><trans-title>Calcium antagonists: choice of therapy for arterial hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Государственный научно-исследовательский центр профилактической медицины МЗ и СР РФ</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>28</day><month>08</month><year>2004</year></pub-date><volume>10</volume><issue>4</issue><fpage>173</fpage><lpage>176</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Марцевич С.Ю., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Марцевич С.Ю.</copyright-holder><copyright-holder xml:lang="en">Martsevich S.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/937">https://htn.almazovcentre.ru/jour/article/view/937</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России, Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3-7.</mixed-citation><mixed-citation xml:lang="en">Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России, Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3-7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Демографический ежегодник России 2002. М, 2002.</mixed-citation><mixed-citation xml:lang="en">Демографический ежегодник России 2002. М, 2002.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian A.V., Bakris G.L., Black: H.R. et al. The Seventh Report q) the John National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.</mixed-citation><mixed-citation xml:lang="en">Chobanian A.V., Bakris G.L., Black: H.R. et al. The Seventh Report q) the John National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003: 21: 1011-53.</mixed-citation><mixed-citation xml:lang="en">Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003: 21: 1011-53.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Opie L., Schall R. Evidence-based evaluations oj calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39: 315-22.</mixed-citation><mixed-citation xml:lang="en">Opie L., Schall R. Evidence-based evaluations oj calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39: 315-22.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Staesssen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002. 15: 85S-93S.</mixed-citation><mixed-citation xml:lang="en">Staesssen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002. 15: 85S-93S.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L., Zanchetti A.,. Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hyper-tension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 1998: 351: 1755-62.</mixed-citation><mixed-citation xml:lang="en">Hansson L., Zanchetti A.,. Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hyper-tension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 1998: 351: 1755-62.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Psaty B.M., Heckhert S.R., Koepsell T. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995: 274: 620-5.</mixed-citation><mixed-citation xml:lang="en">Psaty B.M., Heckhert S.R., Koepsell T. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995: 274: 620-5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002: 288: 2981-97.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002: 288: 2981-97.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention OS a Goal in Hypertension Treatment (INSIGHT). Lancet 2000: 356: 366-72.</mixed-citation><mixed-citation xml:lang="en">Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention OS a Goal in Hypertension Treatment (INSIGHT). Lancet 2000: 356: 366-72.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L., Lindholm L.H., Niskanen L. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in Old patients with Hypertension-2 study. Lancet 1999: 354: 1751-6.</mixed-citation><mixed-citation xml:lang="en">Hansson L., Lindholm L.H., Niskanen L. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in Old patients with Hypertension-2 study. Lancet 1999: 354: 1751-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Staesssen J., Fagard R., This I. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997: 350; 757-764.</mixed-citation><mixed-citation xml:lang="en">Staesssen J., Fagard R., This I. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997: 350; 757-764.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко И.П., Дмитриева Н.А. Проблема выбора лекарственного препарата при лечении артериальной гипертонии. Кардиоваскуляр. тер. и профилактика 2004: 3 (1) 100-4.</mixed-citation><mixed-citation xml:lang="en">Марцевич С.Ю., Кутишенко И.П., Дмитриева Н.А. Проблема выбора лекарственного препарата при лечении артериальной гипертонии. Кардиоваскуляр. тер. и профилактика 2004: 3 (1) 100-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Мешковский А.Н. Место дженериков в лекарственном обеспечении. Фарматека. 2003: 3: 103-4.</mixed-citation><mixed-citation xml:lang="en">Мешковский А.Н. Место дженериков в лекарственном обеспечении. Фарматека. 2003: 3: 103-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.И., Дмитриева Н.А., Белолипецкая В.Г. Выбор лекарственного препарата в кардиологии: на что должен ориентироваться практический врач? Кардиоваскуляр. тер. и профилактика 2004: 4: 77-82.</mixed-citation><mixed-citation xml:lang="en">Марцевич С.Ю., Кутишенко Н.И., Дмитриева Н.А., Белолипецкая В.Г. Выбор лекарственного препарата в кардиологии: на что должен ориентироваться практический врач? Кардиоваскуляр. тер. и профилактика 2004: 4: 77-82.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Carter B.L., Noyes M.A., Demmler R.W. Differences in serum concentrations of and response to generic verapamil in the elderly. Pharmacotherapy 1993: 13: 359-68.</mixed-citation><mixed-citation xml:lang="en">Carter B.L., Noyes M.A., Demmler R.W. Differences in serum concentrations of and response to generic verapamil in the elderly. Pharmacotherapy 1993: 13: 359-68.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
